Edition:
India

Integra LifeSciences Holdings Corp (IART.OQ)

IART.OQ on NASDAQ Stock Exchange Global Select Market

58.98USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$58.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
200,221
52-wk High
$59.30
52-wk Low
$42.25

Latest Key Developments (Source: Significant Developments)

Integra Lifesciences Q4 Adjusted Earnings Per Share $0.64
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Integra Lifesciences Holdings Corp ::INTEGRA LIFESCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $0.64.Q4 GAAP EARNINGS PER SHARE $0.56.Q4 REVENUE ROSE 44.2 PERCENT TO $368.6 MILLION.SEES FY 2018 GAAP EARNINGS PER SHARE $0.60 TO $0.70.SEES FY 2018 REVENUE $1.46 BILLION TO $1.48 BILLION.SAYS FY 2018 ADJUSTED EARNINGS PER SHARE TO BE AT HIGH END OF PREVIOUSLY PROVIDED RANGE OF $2.25 TO 2.35.SAYS EXPECT Q1 ORGANIC GROWTH TO BE IN LOW SINGLE-DIGITS.FY2018 EARNINGS PER SHARE VIEW $2.30, REVENUE VIEW $1.47 BILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $0.56, REVENUE VIEW $356.4 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Integra Lifesciences Holdings Reports Q4 EPS Of $0.56
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Integra Lifesciences Holdings Corp ::INTEGRA LIFESCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $0.64.Q4 GAAP EARNINGS PER SHARE $0.56.Q4 REVENUE ROSE 44.2 PERCENT TO $368.6 MILLION.INTEGRA LIFESCIENCES HOLDINGS SEES FY 2018 REVENUE TO BE AT HIGH END OF $1.46 BILLION TO $1.48 BILLION .SEES FY 2018 GAAP EARNINGS PER SHARE $0.60 TO $0.70.SAYS FY 2018 ADJUSTED EARNINGS PER SHARE TO BE AT HIGH END OF PREVIOUSLY PROVIDED RANGE OF $2.25 TO $2.35.SAYS EXPECT Q1 ORGANIC GROWTH TO BE IN LOW SINGLE-DIGITS.FY2018 EARNINGS PER SHARE VIEW $2.30, REVENUE VIEW $1.47 BILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $0.56, REVENUE VIEW $356.4 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Integra Lifesciences Announces Preliminary Q4 Earnings Per Share View $0.55, Revenue View $351.0
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Integra Lifesciences Holdings Corp ::- ‍ORGANIC REVENUE GROWTH IN Q4 IS EXPECTED TO BE ABOUT 5.5%, ABOVE COMPANY'S IMPLIED GUIDANCE OF ABOUT 4%​.- ‍IS STILL EVALUATING IMPACT OF TAX CUTS AND JOBS ACT OF 2017 ON ITS GAAP FINANCIAL RESULTS​.INTEGRA LIFESCIENCES ANNOUNCES PRELIMINARY FOURTH QUARTER 2017 FINANCIAL RESULTS.SEES Q4 2017 REVENUE ABOUT $365 MILLION.Q4 EARNINGS PER SHARE VIEW $0.55, REVENUE VIEW $351.0 MILLION -- THOMSON REUTERS I/B/E/S.INTEGRA LIFESCIENCES-Q4 2017 ADJUSTED EPS, EXCLUDING IMPACT FROM TAX CUTS,JOBS ACT OF 2017,TO EXCEED HIGH-END OF PREVIOUS GUIDANCE RANGE OF $0.53 TO $0.57.  Full Article

Integra Lifesciences Holdings Corp ‍Reaffirms 2017 Financial Guidance As Provided On Oct 26, 2017​
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Integra Lifesciences Holdings Corp ::- ‍REAFFIRMING 2017 FINANCIAL GUIDANCE AS PROVIDED ON OCTOBER 26, 2017​.- ‍REAFFIRMING 2018 ADJUSTED EARNINGS PER SHARE IN RANGE OF $2.25 TO $2.35​.INTEGRA LIFESCIENCES SAYS PROVIDING 2018 PRELIMINARY REVENUE ESTIMATE IN RANGE OF $1.46 BILLION TO $1.48 BILLION - SEC FILING.INTEGRA LIFESCIENCES - ESTABLISHING FIVE-YEAR FINANCIAL TARGETS OF ABOUT $2 BILLION IN REVENUE AND AN ADJUSTED EBITDA MARGIN RANGE OF 28% TO 30%.FY2018 EARNINGS PER SHARE VIEW $2.30 -- THOMSON REUTERS I/B/E/S.FY2017 EARNINGS PER SHARE VIEW $1.85, REVENUE VIEW $1.17 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Capital Research Global Investors Reports 11.1 Pct Passive Stake In Integra Lifesciences As Of Nov 30
Saturday, 9 Dec 2017 

Dec 8 (Reuters) - Integra Lifesciences Holdings Corp ::CAPITAL RESEARCH GLOBAL INVESTORS REPORTS 11.1 PERCENT PASSIVE STAKE IN INTEGRA LIFESCIENCES HOLDINGS CORP AS OF NOVEMBER 30 - SEC FILING.  Full Article

Integra Lifesciences Q3 adjusted earnings per share $0.45
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Integra Lifesciences Holdings Corp ::Integra Lifesciences reports third quarter 2017 financial results.Q3 adjusted earnings per share $0.45.Q3 GAAP earnings per share $0.04.Q3 revenue $279 million versus I/B/E/S view $286.1 million.Q3 earnings per share view $0.47 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $1.83 to $1.87.Sees FY 2017 gaap earnings per share $0.24 to $0.30.Sees FY 2017 revenue $1.165 billion to $1.175 billion.Integra Lifesciences Holdings Corp - "‍we expect some storm-related disruptions to continue to impact revenues in Q4"​.Integra Lifesciences Holdings Corp - ‍full-year 2017 organic revenue growth is now expected to be about 4 pct​.FY2017 earnings per share view $1.91, revenue view $1.15 billion -- Thomson Reuters I/B/E/S.  Full Article

Natus to acquire neurosurgery assets from Integra Lifesciences
Monday, 11 Sep 2017 

Sept 11 (Reuters) - Natus Medical Inc :Natus to acquire neurosurgery assets from Integra Lifesciences, enters neurosurgery market.Natus Medical Inc - deal for ‍all cash transaction for $47.5 million​.Natus Medical Inc - deal for ‍$47.5 million​.Natus Medical Inc - ‍natus will use cash on hand and available from its credit facility to fund acquisition​.Natus Medical Inc - ‍as part of deal, Natus will acquire global Camino Icp monitoring product line, including its San Diego manufacturing facility​.Natus Medical - ‍sale also includes U.S. rights relating to Integra's fixed pressure shunts, U.S. rights to Codman's duraform dural graft implant​.Natus Medical Inc - ‍expect deal to be immediately accretive to earnings with gross and operating margins similar to our consolidated margins​.  Full Article

Integra Lifesciences reports Q2 adjusted earnings of $0.45/shr
Wednesday, 26 Jul 2017 

July 26 (Reuters) - Integra Lifesciences Holdings Corp :Integra lifesciences reports second quarter 2017 financial results.Q2 adjusted earnings per share $0.45.Q2 GAAP earnings per share $0.14.Q2 revenue $282.2 million versus I/B/E/S view $283.7 million.Q2 earnings per share view $0.45 -- Thomson Reuters I/B/E/S.Integra Lifesciences Holdings Corp says maintaining previously issued 2017 full-year GAAP and adjusted earnings per share guidance.Sees FY 2017 revenue $1.125 billion to $1.14 billion.Integra Lifesciences -revising 2017 full-year organic sales growth to a new range of 6.0% to 7.0% from its previous guidance of 7.0% to 8.5%.FY 2017 earnings per share view $1.92, revenue view $1.13 billion -- Thomson Reuters I/B/E/S.  Full Article

UK's CMA clears Integra Lifesciences, Codman Neurosurgery deal
Thursday, 6 Jul 2017 

July 6 (Reuters) - UK's Competition and Markets Authority::Cleared the anticipated acquisition by Integra Lifesciences Holdings of Codman Neurosurgery Business, using the ‘de minimis’ exception.  Full Article

Integra LifeSciences Q1 adjusted earnings per share $0.39
Wednesday, 26 Apr 2017 

April 26 (Reuters) - Integra LifeSciences Holdings Corp ::Integra LifeSciences reports first quarter 2017 financial results.Q1 adjusted earnings per share $0.39.Q1 GAAP earnings per share $0.08.Q1 revenue $258.6 million versus I/B/E/S view $253.9 million.Q1 earnings per share view $0.40 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $1.12 billion to $1.14 billion.Maintaining previously issued 2017 full-year sales, organic growth, EPS and cash flow guidance.Fy2017 earnings per share view $1.91, revenue view $1.13 billion -- Thomson Reuters I/B/E/S.  Full Article